Executive Order Targets Prescription Drugs & Health Insurance to Promote Competition

Read the complete Executive Order online.

The ACR supports efforts to reduce the cost of high-priced treatments for patients with rheumatic diseases, as long as the ability of rheumatologists and healthcare teams to provide safe and effective treatment is not restricted.² The ACR will also be monitoring implementation efforts and be prepared to advocate against the Most Favored Nation (MFN) model if the Centers for Medicare & Medicaid Services introduces it again in response to this Executive Order.

Reference

Fact Sheet: Executive order on promoting competition in the American economy. WhiteHouse.gov. 2021 Jul 9.
American College of Rheumatology. 2021 ACR top priorities. 2021.

It started with an inhaler. Like many of you, I am a rheumatologist. And like you, I see some patients more often their own primary care provider. This is so often the case that I have gradually devolved into their backup, all-purpose doctor. I am the doc they notify when they get hospitalized for pneumonia…

Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…

The Mark Cuban Cost Plus Drug Co. (CPD) launched in January 2022 to distribute and home deliver prescribed generic medications to consumers. The Texas-based business seeks to reduce the prices of generic drugs by leapfrogging financial negotiators and going straight to drug companies for supply, according to a news release.1 “It’s crazy that medications are…

SAN DIEGO—Pharmacy benefit managers (PBMs) and their impact on drug prices and access to high-cost medications by the patients rheumatologists treat was a major theme at the 2017 ACR/ARHP Annual Meeting Nov. 3–8. In one session, industry experts tried to clarify the role for prior authorizations and drug formulary policies and explored ways to constructively…

Generic-Drug Price Fixing: Is It Happening?

The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

Mark Cuban: Mixing Up the Pharmaceutical Landscape

Rheumatologists Air Frustrations with Pharmacy Benefit Managers at Annual Meeting

Related Articles